on process validation, process validation is defined as the documented evidence that a process consistently produces a product meeting its predetermined specifications and quality attributes. The FDA’s guidance encompasses various guidelines, including ICH Q8, Q9, and Q10, which provide a modern, risk-based approach to validation. Federal regulations set forth in 21 CFR Part 211 and 21 CFR Part 820 further outline the expectation for manufacturers to conduct thorough evaluations, including validation impact assessments, whenever a change is introduced that affects the manufacturing process.

PPQ refers specifically to the conclusive stages of the process validation lifecycle, focusing on proving that a facility and its processes are capable of consistently delivering outputs that meet quality specifications. Change control procedures are crucial here, as they determine whether a change requires a new PPQ execution or if a partial qualification will suffice.

Key Drivers for PPQ Reruns

One of the principal aims of quality risk management is to ascertain whether changes impact the validated state of a process. Several change types warrant a PPQ rerun or partial requalification:

• Raw Material Changes: Any modification in the source, composition, or manufacturer of raw materials could impact product quality and, thus, trigger a revalidation. If suppliers change or if new materials are introduced, a careful assessment is required.
• Equipment Modifications: Changes to any manufacturing equipment—such as upgrades, replacements, or even routine maintenance—can affect the process performance. Assess whether the new machinery delivers the same outputs as the previous equipment and whether it maintains required specifications.
• Process Changes: Any alteration in the production or testing process, such as a change in parameters (temperature, pressure, time), can result in a divergence from the established validated process and will necessitate a revalidation.
• Facility Changes: If there are significant modifications to the facility such as upgrades or changes in layout that could affect methods of operation, environmental conditions, or personnel workflows, a re-evaluation is necessary.
• Change in Suppliers: The introduction of new suppliers, particularly for critical components, often requires a reassessment of previously validated processes to ensure consistency in quality.

These change types are not exhaustive. Each modification should be evaluated with robust risk assessments according to the criteria outlined in ICH Q9.

Partial Requalification vs. Full PPQ Rerun

Determining when to perform a full PPQ rerun versus a partial requalification is often contingent upon a variety of company-specific factors, including the significance of the change, the level of validation backlog, and regulatory expectations. Certain changes may be less significant and thus allow for a partial requalification, saving time and resources while maintaining compliance.

In contexts where the intent is not to overhaul a whole process, highlighting the scope of changes within a control strategy is paramount. A review of Committee for Medicinal Products for Human Use (CHMP) guidelines may provide further insights into the EU’s perspective on significant versus minor changes.

• Emergency Changes: In crisis situations where unplanned modifications are necessary, a company might be permitted to execute an expedited revalidation that focuses on risk mitigation rather than rigorous adherence to protocol.
• Established Variations: Moving forward with changes classified as ‘business as usual’—those that have been previously validated and are consistently assessed—might fit into a model allowing for partial requalification.

Lifecycle Process Validation and Change Control

Change Control (CC) is crucial within the lifecycle of process validation. The system should adhere to predetermined operating procedures that define how changes will be managed and documented at all stages, from conception through execution and into post-implementation review. Regulatory bodies have emphasized the integration of quality systems with change control to achieve a compliant lifecycle process validation.

In line with the FDA’s guidance on Quality by Design (QbD), the emphasis is placed on assessing the risk associated with changes using a CPV (Continual Process Verification) approach. This leads to CPV-based decisions on whether changes are acceptable without further extensive validation efforts. Establishing KPIs related to the performance metrics provides tangible data for decision-making and ensures compliance with both FDA and EMA regulations.

Validation Impact Assessment (VIA)

Conducting a Validation Impact Assessment (VIA) is a critical component of determining the gravity of a proposed change. A VIA evaluates the potential effect of a change on validated processes, outcomes, and product quality over the lifecycle of the product.

The assessment should follow these steps:

• Define the Change: Clearly outline what the change entails and its expected outcome.
• Document Current Validated State: Record the existing validated parameters, focusing on performance outputs while ensuring the stability and consistency of quality attributes.
• Risk Assessment: Employ methods such as Failure Mode and Effects Analysis (FMEA) to evaluate the risks associated with the proposed changes.
• Determine Actions Required: Based on the risk assessment, identify whether a full PPQ rerun, partial requalification, or monitoring and documentation will suffice.
• Feedback Loop: After executing the change, collect and analyze data to validate that the modifications have not adversely impacted the process. Assess feedback against predetermined KPIs to inform future decisions.

Global Considerations and Conclusion

The framework surrounding change control and revalidation is not exclusive to the US; understanding global revalidation practices is crucial for firms operating in multiple regulatory environments, such as the EU and UK. Each ecosystem has its regulatory nuances, and aligning these processes helps streamline compliance efforts across jurisdictions.

The CDER and CBER have issued guidance documents that address the topic of lifecycle process validation and change control. These resources are invaluable for professionals navigating revalidation triggers as they provide precise insights into the expectations of regulatory authorities. Ensuring adherence to such guidelines is crucial for maintaining the integrity of product quality and regulatory standing.

In conclusion, recognizing and understanding the various triggers for PPQ reruns or partial requalification is essential for professionals in the pharmaceutical sector. With the ever-increasing complexity of pharmaceutical manufacturing processes and heightened regulatory scrutiny, a proactive approach to change control and thorough validation can mitigate risks and enhance product quality while ensuring compliance with FDA regulations.